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Abstract  
Background 
Both UW and HTK are currently used in the Eurotransplant region for preservation of 
liver allografts. Previous studies on their effect have led to a lot of discussion. This 
study aims to compare the effect of HTK and UW on graft survival. 
Methods  
First liver transplantations in adult recipients (≥18 years) from 1.1.2007 until 
31.12.2016 were included. Graft survival was compared for livers preserved with 
HTK and UW at 30 days, 1, 3 and 5-years. A multivariable analysis of risk factors on 
graft survival was performed and outcome was adjusted for important confounders. 
Results 
Of all 10,628 first liver transplantations, 8,176 (77%) and 2,452 (23%) were 
performed with livers preserved with HTK and UW, respectively. Kaplan-Meier 
curves showed significant differences in graft survival between HTK and UW at 30 
days (89% vs. 93%, p=<0.001), 1-year (75% vs. 82%, p=<0.001), 3-years (67% vs. 
72%, p<0.001) and at 5-years (60% vs. 67%, p<0.001). No significant differences in 
outcome were observed in separate analyses of Germany or non-German countries. 
In multivariable analysis, UW was associated with a decreased risk of graft loss at 30 
days (HR 0.772, p=0.002) and at 1 year (0.847 (0.757-0.947). When adjusted for risk 
factors, no differences in long term outcome could be detected. 
Conclusions 
Because the use of preservation fluids is clustered geographically, differences in 
outcome by preservation fluids are strongly affected by regional differences in donor 
and recipient characteristics. When adjusted for risk factors, no differences in long-
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term graft survival exist between transplantations performed with livers that are 
preserved with either HTK or UW. 
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Introduction 
Ischemic injury sustained during organ preservation influences post-transplantation 
outcomes in an important way. Throughout the process of organ preservation, 
preservation fluids are used. In the donor, the liver is perfused with cold preservation 
fluid after cross-clamping of the aorta. It is then packed in a sterile bag filled with this 
same fluid in a box with ice after hepatecomy1. In the transplant hospital, the organ is 
perfused prior to transplantation using the same preservation fluid. Almost all livers 
within Eurotransplant (ET) are preserved by this ‘cold storage’. Other preservation 
techniques such as machine perfusion are currently only performed in an 
experimental way.  
Several preservation fluids are used within the ET region although most countries 
use either University of Wisconsin solution (UW) or histidine-tryptophan-
ketoglutarate solution (HTK)2. The choice of preservation fluid is thought to be 
important for outcome and a difference in effect on outcome has often been studied. 
First studies on the topic could not detect significant differences in short and long 
term patient- and graft survival2–7(table 1). This might have been a result of the 
frequent single-center design and low numbers of included transplantations. A larger 
study by Stewart et al. showed HTK to be associated with a higher risk of early graft 
loss (<30 days) as compared to UW in the UNOS database8. It contributed to a 
gradual change to UW although some centers prefer HTK for the lower viscosity and 
lower costs.  
 
More recent studies of Kaltenborn et al.9 and Adam et al.10 presented conflicting 
results on the issue. Kaltenborn showed only minimal differences between HTK and 
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UW while Adam et al. found HTK to be associated with a significant increased risk of 
long-term graft loss (at least up to five years) as compared to UW in the European 
Liver Transplant Registry(ELTR)10. Several remarks and concerns with the design of 
the study and its conclusions were placed by Nashan et al.11. Most important 
concerns were with including living donation, insufficient risk adjustment and the 
overrepresentation of German livers in the HTK group. Germany uses HTK 
exclusively and it has a MELD based allocation combined with one of the lowest 
donor rates of Europe12. The difference in long-term outcome that was attributed to 
HTK in this study might rather reflect inferior outcomes in general in Germany. In 
response, Adam et al. published an analysis without living donors and German 
centers and more recently, an analysis based on propensity score matching13,14. This 
analysis matched patients on ABO compatibility, recipient ischemic time≥6 hours, 
gender, study period (2003-2007 vs. 2008-2012), recipient age≥60 years, donor 
age≥55 years, whole liver, urgency of transplantation, hepatocellular carcinoma, 
recipient HIV status and centers performing more than 10 liver transplantations from 
living donors. Although an association between HTK and graft loss could be seen, 
we believe that inter-regional differences in donor, transplant and recipient 
characteristics were insufficiently taken into account. 
 
This study aims to evaluate the effect of HTK and UW on short- and long term 
outcome after liver transplantation in the Eurotransplant region, with adequate 
adjustment for (regional) differences in donor, transplant and recipient factors. 
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Patients and methods 
Data selection 
All first transplantations from deceased donor livers performed in adult recipients 
(≥18 years) from January 1, 2007 until December 31, 2016 were included. 
Transplantations with livers from donors after circulatory death (DCD) (n=771), split 
allografts (n=380) and allografts from donors outside of Eurotransplant were 
excluded. When information on the used preservation fluids was missing (n=160)  or 
when preserved with other preservation fluids than HTK or UW  fluid (Celsior n=18, 
Eurocollins=1, IGL-1 n=79 and other n=216) transplantations were also excluded as 
well as transplantations performed in patients with a high-urgency status (n=888), 
with a combination other than liver/kidney and transplantations performed in 
Gӧttingen15. Transplantations were categorized in either HTK or UW according to the 
preservation fluid that was used during procurement and subsequent transport. 
Follow-up data were obtained from the Eurotransplant Network Information System 
(ENIS) and Eurotransplant (ET) Liver Registry up to September 2017. All data were 
anonymized for transplant center and patient related data with exception of country. 
The study protocol was approved by the Eurotransplant Liver Intestine Advisory 
Committee (ELIAC) and no ethical statement was required according to European 
guidelines and Dutch law.  
 
Data analysis 
Laboratory values were converted to standardized units and in case of missing 
values <2%, median values were used; gamma-glutamyl-transpeptidase (GGT) 38 
U/L (1.8%) and recipient body mass index (BMI) 25.8 (0%). The Eurotransplant-
Donor Risk Index (ET-DRI)16 was calculated for all transplanted livers and the 
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simplified recipient risk index (sRRI)17 was calculated for all recipients based on 
most recent laboratory Model for End Stage Liver Disease (MELD) score before 
transplantation. With the ET-DRI and sRRI the Donor-recipient Model (DRM) was 
calculated for all transplantations18. Serum creatinin value was set at 4 mg/d therapy 
according to ET guidelines for patients receiving renal replacement, MELD score 
was rounded to the nearest whole value (range 6-40). Donor HCVAb, donor HBCAb, 
recipient HCVAb, dialysis of the recipient prior to transplantation and a history of 
diabetes in the donor were considered negative if not tested or missing. Rescue 
allocation is a center-oriented allocation after patient-oriented allocation and is 
started for short allocation time or medical reasons. Clinical characteristics were 
summarized by median and 25% and 75% interquartile ranges (IQR) and number 
and percentage (N/%) for respectively continuous and categorical variables. 
Numerical and categorical factors between groups were compared using Kruskall-
Wallis and Chi-square tests. 
 
Outcome measures 
Primary outcomes used in the analyses were 30 days, 1, 3 and 5-year non death-
censored graft survival. Secondary outcomes were 30 days, 1,3 and 5-year patient 
survival (PS). Graft survival was defined as the time period between date of 
transplantation and date of re-transplantation or patient death. Patient survival was 
defined as the time period between date of transplantation and date of patient death. 
Outcome was analyzed by Kaplan Meier analysis and log-rank tests when stratified 
by preservation fluid category (HTK, UW). Results were also stratified for 
transplantation region and preservation fluid (Germany+HTK, Germany+UW and 
Non-Germany+HTK, Non-Germany+UW).  
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Risk factors  
To identify risk factors associated with graft survival, multivariable analysis was 
performed in a Cox regression analysis (backward selection) for all transplantations 
and included factors described to be associated with graft survival16,18–20.  These 
factors included donor age, cause of death, sex, BMI, latest GGT, HBcAb, HCVAb, 
history of diabetes, Recipient age, sex, BMI, laboratory MELD score at 
transplantation, etiology of primary liver disease, liver/kidney combination, dialysis 
prior to transplantation, total ischemic time, rescue allocation, allocation region (local, 
regional, extra-regional) and year of transplantation (continuous). Graft survival was 
then adjusted for all risk factors associated with 5-years graft survival in Germany, 
non-German countries and all transplantations. A potential effect of preservation 
fluids in HCC patients or in livers with longer cold ischemic times was described in 
literature10. This potential relation was analyzed with Kaplan-Meier analysis and in a 
Cox-regression analysis when adjusted for risk factors. 
 
For all analyses a Wald p-value of < 0.05 was considered significant. Survival 
analyses were performed using Kaplan-Meier survival models and multivariable 
analyses were performed using Cox regression models. All analyses were performed 
with SPSS (version 24.0). 
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Results 
Within the study period, 10,628 first liver transplantations were included. Median 
donor age of all transplantations was 55 years old (IQR 45-67) and median donor 
BMI 26 (IQR 24-28). Cerebro-vascular accident was the most frequent cause of 
death (62%) followed by trauma (20%). Near half of donors was allocated extra-
regionally (46%) and median ET-DRI was 1.84. Most recipients were male (70%) 
and had a median age 56 years old and median BMI of 25. Transplanted recipients 
had a median laboratory MELD score of 16 and a median match MELD score of 24. 
Alcoholic disease was most frequent primary diagnosis (27%) followed by malignant 
disease (25%) and other cirrhosis (14%). The majority of transplantations was 
performed in Germany (62%) followed by Belgium (12%) and Austria (10%). Median 
sRRI was 1.86 and median DRM was 2.77. 
Preservation fluid category 
Of all transplantations, 8,176 (77%) and 2,452 (23%) were performed with livers 
preserved with HTK and UW, respectively. The relative use of UW decreased from 
36% in 2007 to 18% in 2016 while the use of HTK increased from 64% to 82% 
(figure 1). Within donor countries strong preference for either HTK or UW during 
procurement was seen. HTK is preferred in Hungary (100%), Germany (98%), 
Slovenia (97%) and Austria (84%) while UW is preferred in The Netherlands (98%), 
Croatia (83%), Belgium (73%) and, with very small numbers, Luxembourg (100%).   
Median donor age and BMI were significantly higher in the HTK group as compared 
to the UW group (56 vs. 55 years old, p<0.001) and (26 vs. 25, p<0.001), 
respectively. Cause of death of the donor was significantly different between both 
groups (p<0.001); less trauma (17% vs. 26%) and more often anoxia (13 vs. 3%) 
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were registered as cause death in the HTK group. Total ischemic times were longer 
in the HTK group in comparison to the UW group (8.6 vs. 7.3 hours) and HTK livers 
were more often accepted in rescue allocation (32 vs. 16%, p<0.001). The median 
ET-DRI was significantly higher in the HTK group (1.90 vs. 1.66, p<0.001).  
Recipient age and BMI were not different in both the UW and HTK group with a 
median of 56 years old (p=0.093) and BMI of 26 (p=0.390), respectively. Although 
both groups had a similar median laboratory MELD score, the distribution was not 
equal (p<0.001). As compared to the UW group, the HTK group has a higher 
proportion of transplanted MELD 25-35 (14% vs. 13%) and MELD 35+ recipients 
(13% vs 6%).  Also, the match MELD did vary between HTK and UW (25 vs. 22, 
p<0.001). Median sRRI showed only minor differences while the DRM was 
significantly higher in the HTK group 2.85 vs. 2.56 (p<0.001), data shown in table 2. 
 
Outcome 
For all transplantations, graft survival at 30 days, 1, 3 and 5-years was 90%, 77%, 
68% and 62%, respectively. Graft survival was significantly better in the UW group 
as compared to HTK at 30 days (93% vs. 89%, p=<0.001), 1-year (82% vs. 75%, 
p=<0.001), 3-years (72% vs. 67%, p<0.001) and at 5-years (67% vs. 60%, p<0.001), 
as shown in figure 2a. Similar differences were found in patient survival (PS); 
transplantations with UW preserved livers showed better PS as compared to HTK at 
30 days (95% vs. 93%, p=<0.001), 1-year (86% vs. 79%, p=<0.001), 3-years (78% 
vs. 71%, p<0.001) and at 5-years (72% vs. 65%, p=<0.001), as shown in figure 2b.  
Within Germany, 6,174 transplantations were performed with HTK and 463 with UW. 
In non-German countries 2,029 and 1,989 transplantations were performed with HTK 
and UW preserved livers, respectively. Outcome stratified for transplantation region 
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(Germany/non-Germany) and preservation fluid (HTK/UW) showed significantly 
lower overall graft survival in Germany. Within both regions, a trend for a slightly 
higher graft survival on short-term was seen for UW preserved livers as compared to 
HTK livers. On long-term, HTK livers showed a trend towards better graft survival. 
This was observed in Germany at 30 days (HTK 87% vs. UW 88%), 1-year (HTK 
72% vs. UW 73%), 3-years (HTK 64% vs. UW 64%) and at 5-years (HTK 57% vs 
UW 56%). In Non-Germany this was also observed at 30 days (HTK 93% vs. 94%), 
1 year (HTK 83% vs. 84%),3 years (HTK 76% vs. UW 74%) and at 5 years (70% vs. 
70%) (data shown in figure 4).  Differences in outcome within both regions were not 
statistically significant at any time point.  
 
Risk factors  
In multivariable analysis, donor age, total ischemic time, donor last GGT, a history of 
diabetes in the donor, allocation region, rescue, recipient age, sex, etiology of liver 
disease, dialysis prior to transplantation, laboratory MELD score and year of 
transplantation were associated with 5-year graft survival. An association between 
outcome and preservation fluids could only be detected on short-term. UW was 
associated with a decreased risk of graft loss at 30 days (HR 0.762, CI 0.643-0.902, 
p=0.002) and at 1 year (HR 0.835, CI 0.746-0.0.934, p=0.002), data are shown in 
table 3. When adjusted for all risk factors associated with 5-years graft survival, no 
difference could be detected between both preservation fluids in transplantations 
performed in Germany (p=0.572) (figure 4a) or Non-Germany (p=0.522) (figure 4b). 
In all transplantations, also no difference in long-term outcome could be shown (data 
are shown in figure 4c).  
Risk groups 
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Of all transplantations, 3527 (33%) of patients had a registered HCC. Patients with 
HCC had lower graft survival when transplanted with a liver preserved with HTK 
(n=2,747) as compared to livers preserved with UW (n=780) at 30 days (90% vs. 
93%, p=0.013) and at 1 year (77% vs. 81%, p=0.006). When adjusted for other risk 
factors, a potential effect of HTK or UW in HCC patients was not observed at 30 
days (p=0.557) or at 1 year (p=0.424).  
When transplantations were stratified according to the ELTR total ischemic times 
categories, three groups were identified; livers transplanted with <=6 hours 
(n=2,700), 6-12 hours (n=6,231) and >=12 hours (n=1,697) of cold ischemic time. 
Only in transplantations performed with livers with 6-12 hours of cold ischemic time a 
statistically significant difference between HTK and UW could be observed (60% vs. 
69%, p<0.001) (data are shown in figure S1a-c). When adjusted for other risk 
factors, or when analyzed per region (Germany vs. non-Germany) this potential 
negative impact of HTK in livers with longer cold ischemic times was not observed 
(data are shown in figure S2-3a,b,c,).  
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Discussion 
 
This study shows that HTK is used in the majority of organ transplantations within 
Eurotransplant. The use of HTK is increasing, in contrast to UW. Overall graft 
survival is lower for livers preserved with HTK, but these results are strongly affected 
by regional differences in donor, recipient and transplant characteristics. When 
adjusted for these risk factors, no difference between HTK and UW could be 
observed.   
 
The issue of preservation fluids remains an important point of discussion in liver 
transplantation. While evidence is still considered non-conclusive, different 
preservation fluids are currently used. This study shows, that although UW is 
internationally considered the golden standard, the relative use of UW within ET is 
decreasing while the use of HTK is increasing. To compare the effect of both 
preservation fluids, we have tried to ensure a homogenous study population. We 
have excluded all pediatric recipients, those receiving living related livers, livers from 
DCD donors, split livers and transplantations in high-urgent patients.  Even with 
these strict inclusion criteria, this study includes a sufficiently high number of 
transplantations to detect minor differences in outcome and to perform an adequate 
multivariable analysis. The unfavorable characteristics of the group of livers 
preserved with HTK are likely to have contributed to the inferior graft- and patient 
survival. We have therefore separated our analysis per region, and have adjusted 
outcome for risk factors to interpret the differences in graft- and patient survival. The 
high completeness for important data like total ischemic times and MELD score add 
to the reliability of our findings. Although performed with care, risk adjustment may 
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still not be sufficient as is inherent to the retrospective design. We considered graft 
survival as primary outcome and did not have information on biliary complications or 
early bile production. This is a potential limitation, because some studies found 
suggestions for more post-transplantation bile production and less biliary 
complications in livers that were preserved with HTK21. However, biliary 
complications will likely also affect graft-survival in the long run.   
 
The presented results of inferior unadjusted graft survival between HTK and UW are 
in line with the previously published study  by the ELTR10. The ELTR study attributed 
this inferior long-term outcome to the use of HTK. Interesting, because the risk of 
HTK on graft loss was one of the lowest of all risk factors and only just statistically 
significant (RR 1.1, p=0.02) in over 34,500 transplantations10. Based on our findings, 
differences in long-term outcome in particular, are more likely to reflect differences in 
donor, recipient and transplant risks than an effect of the preservation fluid itself. 
When these differences are adequately taken into account no statistically significant 
difference could be detected between HTK and UW. This finding is in accordance to 
other studies that could not show any significant differences between HTK and UW2–
7. Although this could be a result of an inadequate power due to small numbers, also 
Kaltenborn et al.9  neither have shown a difference in risk between both fluids 
despite a sizeable dataset (summary in table 1). A slightly better short term graft 
survival in livers preserved with UW, as reported by Stewart et al.8, may be present 
according to the risk adjusted survival in non-German countries (figure 4b).   
 
Some studies have also described a more pronounced effect of preservation fluids in 
several subgroups. This would affect livers from DCD donors8, livers with total 
  14 
ischemic times >12 hours10, patients with a HCC10 and split liver allografts10. A 
potential difference in DCD donors and split procedures could not be analyzed 
because these were excluded in this study. Differences in the other mentioned 
subgroups (categorical total ischemic time groups, HCC recipients) were not 
confirmed in this study or did not persist when adjusted for other risk factors.  
 
To correctly interpret differences in outcome between several preservation fluids, the 
hypothesized causative pathway is important. The mechanism through which HTK 
would be inferior is however, currently still unclear. It could be related to differences 
in composition and viscosity2 which might lead to different effects in liver cell volume, 
efficiency of wash-out or to the presence of antioxidant agents22,23. These effects 
would, in theory, especially affect short term graft survival.  
 
The differences in donor, transplant and patient characteristics between HTK and 
UW are primarily a result of the national choice of preservation fluids. Germany, for 
example, used HTK in 97% of all procurements and in 93% of their transplantations 
(the difference is because of international exchange within Eurotransplant). When 
compared to all HTK transplantations in Eurotransplant, 75% of all HTK preserved 
livers are transplanted in Germany. A country that has been struggling with one of 
the lowest DBD donor rates in Europe12 and has implemented a MELD based 
allocation system. Both are likely to impact post-transplantation outcome in a 
negative way (figure 3). Due to the low donation rates, limits for liver allografts have 
been stretched and liver grafts are in general of lower quality; higher donor age, lab 
values and BMI. Also, because of the shortage of grafts, the waiting list expands and 
recipients will only be able to receive an offer when their MELD-score raises24.  
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For this reason, outcome was stratified for Germany versus all other countries. It is 
therefore interesting, that transplantations with HTK livers showed a trend for similar 
or better graft survival as compared to UW in both regions although this difference 
was not statistically significant. This statistical phenomenon where findings in 
subgroups are apparently contradictory to overall results is called a Simpson’s 
paradox. It can exist when different sample sizes are compared of groups with 
different outcome. In this case, because of discrepancies in the use of preservation 
fluids between countries with different post-transplantation outcome. The latter 
affects outcome of UW livers in Germany: Germany almost exclusively uses HTK so 
livers perfused with UW are likely to originate from other ET-countries. This is the 
case for livers that were not accepted for transplantation in the donor country.  
 
The significant differences in outcome within Eurotransplant are also observed when 
results from ET are compared to the US. The presented 1-year graft survival rates in 
non-German countries of about 83% are significantly lower than the approximately 
90% 1-year graft survival for first liver transplantations in the US in 201625. We 
believe that a difference in liver quality between ET and the US attributes to this 
difference in outcome. This difference in donor quality was shown by Blok et al. in 
201226 and is evident for donor age; about 66% of all livers used for a transplant in 
the US in 2016 were from donors younger than 50 years old25 as compared to 36% 
in ET (median was 55 years old)24. This might be a result of regulation on center 
outcome as is done in the US or by an assumed higher shortage of organs in ET. 
Regardless of the reason(s), the difference in donor quality shows that centers in ET 
have expanded their criteria for acceptable donors to increase the number of 
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patients that can be transplanted and to decrease waiting list mortality. This strategy, 
however, comes at the cost of slightly inferior post-transplantation outcome.  
 
In deciding what preservation fluid to use, the experience of surgeon and center 
should be the most important consideration. Our results indicate that no significant 
difference exists between both preservation fluids. Other aspects, like the lower 
viscosity, which is often appreciated by clinicians and the lower costs associated with 
the use of HTK might then also be taken into account. 
 
Conclusions 
The use of preservation fluids differs significantly per country within the 
Eurotransplant region. HTK is being used in the majority of liver transplantations and 
its use is increasing, in contrast to the use of UW. This retrospective database 
analysis shows that differences in outcome by preservation fluids are caused by 
regional differences in donor, recipient and transplant characteristics. These 
differences, rather than the used preservation fluid, cause the difference in outcome.  
When adjusted for these risk factors retrospectively, no differences in graft survival 
exist between transplantations performed with livers that are preserved with either 
HTK or UW.  
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Tables  
Table 1. Studies on the use and effect of perfusion fluids in deceased donor liver transplantation 
Author 
Yea
r Journal Short description 
Perfusion 
fluid 
No. 
patients 
Graft survival  
30 days 3 Months 6 Months 1y 3 y 5 y Best 
Adam et al.10 2015 AJT 
Retrospective study on the ELTR 
database HTK 8696 
   77% 69% 64% UW 
    UW 24562 
   83% 75% 69%  
    CE 7756 
   82% 73% 68%  
    IGL 1855 
   82% 75% 68%  
Kaltenborn et 
al.9 2014 
BMC 
Gastroenterology Double center, retrospective study  HTK 1838 
No effect in 3 month graft survival, HTK beneficial on long 
term graft survival in univariate but not in multivariable 
analysis 
HTK 
    UW 1314 
 
Stewart et al.8 2009 AJT 
Retrospective study on the UNOS 
database HTK 4755 HTK vs. UW, OR 1.2 (1.04-1.39, p<0.012) on early graft 
loss (<30 days) in multivariable analysis 
UW 
    UW 12673 
 
Rayya et al77  2008 Transplant Proc. Single center, retrospective study HTK 69 90% 
  71% 71%  UW 
    UW 68 
90%   78% 75%   
Mangus et al. 6 2008 Liver Transplant. 
Single center, retrospective study in 
ECD livers HTK 204 
 89%  84%   HTK 
    UW 231 
 88%  83%    
Meine et al.3  2006 Transplant Proc. 
Single center, randomized, prospective 
study HTK 37 No significant differences in 2 years graft survival (death 
censored) 
N/A 
    UW 65 
 
Avolio et al.5 2006 Transplant Proc. Single center study HTK 14 
  86%     
    UW 21 
  81%     
Mangus et al.4  2006 Liver Transplant. Single center, retrospective study HTK 174 92% 
 86% 81%   UW 
    UW 204 
92%  86% 82%    
Erhard et al.2 1994 Transplant Int. Prospective, randomized study HTK 30 
 87%   77%  HTK 
    UW 30 
 80%   74%   
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Table 2. Donor and recipient characteristics per perfusion fluid, n=10,826 
 HTK Bretschneider (n=8,176) UW (n=2,452) HTK vs. UW 
 
(N (%)/Median (25%/75% 
percentile) 
(N (%)/Median (25%/75% 
percentile) 
p-value 
Donor Factor 
Donor Age (y) 56 (45-67) 55 (43-65) <0.001 
Height (cm) 174 (165-180) 174 (167-180) 0.097 
Weight (kg) 80 (70-90) 76 (68-85) <0.001 
BMI 26 (24-28) 25 (23-28) <0.001 
Last GGT (U/L) 43 (22-99) 31 (17-62) <0.001 
Sex (male) 4,445 (54) 1,366 (56) 0.241 
Cause of death    
<0.001 
Anoxia 1,020 (13) 82 (3) 
Circulational 113 (1) 158 (6) 
CNS Tumor  44 (1) 19 (1) 
CVA/Stroke 5,129 (63) 1,484 (61) 
Trauma 1,426 (17) 648 (26) 
Other 443 (5) 61 (3) 
Diabetes (y) 816 (10) 173 (7) <0.001 
Transplant Factor 
Total ischemic time (h) 8.6 (6.3-11.0) 7.3 (5.0-9.6) <0.001 
Allocation region   
<0.001 
Local 1,980 (24) 1,004 (41) 
Regional 1.902 (23) 892 (36) 
Extra-regional 4,294 (53) 556 (23) 
Rescue (Yes) 2,613 (32) 389 (16) <0.001 
Country    
<0.001 
Germany 6,147 (75) 463 (19) 
Hungary 221 (3) 11 (0) 
Netherlands 124 (2) 465 (19) 
Belgium 476 (6) 752 (31) 
Croatia 196 (2) 593 (24) 
Slovenia 149 (2) 9 (0) 
Austria 863 (11) 159 (7) 
ET -DRI 1.90 (1.59 -2.24) 1.66 (1.40-1.92) <0.001 
Recipient Factor 
Age (y) 56 (49-62) 57 (49-62) 0.093 
Height (cm) 174 (168-180) 173 (167-180) 0.003 
Weight (kg) 80 (69-90) 78 (68-90) 0.019 
BMI 26 (23-29) 26 (23-29) 0.390 
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Laboratory MELD 16 (11-27) 16 (11-23) 0.001 
Match MELD 25 (16-31) 22 (17-27) <0.001 
Exceptional MELD (yes) 2753 (34) 790 (32) 0.181 
Sex (male) 5,759 (70) 1696 (69) 0.228 
Dialysis pre-transplant 1002 (12) 157 (6) <0.001 
Primary diagnosis   
<0.001 
Metabolic 264 (3) 91 (4) 
Acute 158 (7) 28 (1) 
Cholestatic 906 (10) 267 (11) 
Alcoholic 2,112 (24) 716 (29) 
Malignant 2,060 (24) 628 (26) 
HBV 316 (4) 94 (4) 
HCV 867(10) 211 (9) 
Other Cirrhosis 1,146 (13) 295 (12) 
Other 347 (5) 122 (5) 
LabMELD category   
<0.001 
<15 3,515 (43) 1040 (42) 
15-25 2,446 (30) 930 (38) 
25-35 1,136 (14) 329 (13) 
35+ 1,079 (13) 153 (6) 
sRRI  1.87 (1.58-2.23) 1.86 (1.58-2.17) <0.001 
DRM  2.85 (2.31–3.51) 2.56 (2.09-3.08) <0.001 
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Table 3. Multivariable analysis of factors associated with graft survival  
 
 30 days 1 year 3 years 5 years 
 HR (95% CI) 
p-
value HR (95% CI) 
p-
value HR (95% CI) 
p-
value HR (95% CI) 
p-
value 
Donor factor 
Preservation fluid 
(HTK) UW 
0.762 (0.643-
0.902) 
0.00
2 
0.835 (0.746-
0.934) 
0.00
2 * * 
Age *  
1.007 (1.004-
1.009) 
<0.0
01 
1.009 (1.006-
1.011) 
<0.0
01 
1.009 (1.006-
1.011) 
<0.0
01 
Total ischemic time 
(h) 
1.031 (1.015-
1.047) 
<0.0
01 
1.026 (1.015-
1.037) 
<0.0
01 
1.017 (1.007-
1.026) 
0.00
1 
1.016 (1.007-
1.025) 
0.00
1 
Last GGT  
1.001 (1.001-
1.002) 
<0.0
01 
1.001 (1.000-
1.001) 
0.00
6 
1.000 (1.000-
1.001) 
0.02
0 
1.000 (1.000-
1.001) 
0.01
6 
BMI 
1.013 (1.000-
1.027) 
0.05
0 * * * 
Diabetes (no) yes 
1.299 (1.076-
1.570) 
0.00
7 
1.214 (1.065-
1.385) 
0.00
4 
1.231 (1.097-
1.382) 
<0.0
01 
1.207 (1.080-
1.348) 
0.00
1 
Allocation (local) *  
0.03
9  
0.00
3  
0.00
1 
Regional * 
1.077 (0.954-
1.215) 
0.23
0 
1.078 (0.972-
1.196) 
0.15
4 
1.074 (0.974-
1.185) 
0.15
1 
Extra-regional * 
1.158 (1.033-
1.297) 
0.01
2 
1.182 (1.072-
1.303) 
0.00
1 
1.190 (1.085-
1.305) 
<0.0
01 
Rescue (No) Yes 
1.345 (1.159-
1.560) 
<0.0
01 
1.212 (1.091-
1.346) 
<0.0
01 
1.218 (1.113 -
1332) 
<0.0
01 
1.219 (1.121-
1.326) 
<0.0
01 
Recipient factor 
Age * 
1.011 (1.006-
1.015) 
<0.0
01 
1.012 (1.007-
1.016) 
<0.0
01 
1.011 (1.008-
1.015) 
<0.0
01 
Sex (Female) Male * 
1.143 (1.040-
1.256) 
0.00
5 
1.177 (1.083-
1.280) 
<0.0
01 
1.183 (1.092-
1.280) 
<0.0
01 
BMI 
1.016 (1.003-
1.029) 
0.01
7 * * * 
Etiology (Metabolic)  
0.00
2  
0.00
5  
<0.0
01  
<0.0
01 
Acute 
1.897 (1.206-
2.984) 
0.00
6 
1.389 (0.987-
1.954) 
0.05
9 
1.372 (1.008-
1.866) 
0.04
4 
1.398 (1.035-
1.889) 
0.02
9 
Cholestatic 
1.103 (0.751-
1.622) 
0.61
6 
1.135 (0.871-
1.480) 
0.34
8 
1.057 (0.836-
1.336) 
0.64
6 
1.102 (0.877-
1.383) 
0.40
4 
Alcoholic 
0.918 (0.642-
.1.313) 
0.64
1 
0.990 (0.773-
1.267) 
0.93
5 
0.926 (0.745-
1.152) 
0.49
1 
0.990 (0.802-
1.223) 
0.92
8 
Malignant 
1.016 (0.704-
1.466) 
0.93
2 
1.074 (0.832-
1.385) 
0.58
5 
1.116 (0.894-
1.394) 
0.33
2 
1.195 (0.964-
1.481) 
0.10
5 
HBV 
1.023 (0.653-
1.602) 
0.92
1 
0.872 (0.634-
1.201) 
0.40
2 
0.887 (0.672-
1.171) 
0.39
9 
0.913 (0.698-
1.194) 
0.50
5 
HCV 
1.119 (0.764-
1.640) 
0.56
3 
1.271 (0.978-
1.652) 
0.07
3 
1.408 (1.120-
1.769) 
0.00
3 
1.476 (1.183-
1.843) 
0.00
1 
Other cirrhosis 
0.943 (0.648-
1.372) 
0.75
8 
1.010 (0.780-
1.308) 
0.94
0 
1.002 (0.798-
1.258) 
0.98
6 
1.052 (0.843-
1.312) 
0.65
5 
Other/unknown 
1.283 (0.816-
2.016) 
0.28
0 
0.986  (0.706 
-1.378) 
0.93
6 
0.786 (0.581-
1.062) 
0.11
7 
0.823 (0.616-
1.098) 
0.18
6 
SLK (yes) 
0.578 (0.371-
0.901) 
0.01
6 
0.748 (0.567-
0.986) 
0.03
9 * * 
Dialysis pre-transplant 
(no) yes 
1.417 (1.153-
1.742) 
0.00
1 
1.489 (1.296-
1.709) 
<0.0
01 
1.231 (1.097-
1.382) 
<0.0
01 
1.402 (1.246-
1.578) 
<0.0
01 
LabMELD (<15)  
<0.0
01  
<0.0
01  
<0.0
01  
<0.0
01 
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>=15 and <25 
1.044 (0.889-
1.226) 
0.59
8 
1.083 (0.970-
1.209) 
0.15
8 
1.041 (0.947-
1.143) 
0.40
5 
1.042 (0.954-
1.138) 
0.36
3 
>=25 and <35 
1.356 (1.100-
1.671) 
0.00
4 
1.580 (1.374-
1.817) 
<0.0
01 
1.434 (1.268-
1.623) 
<0.0
01 
1.347 (1.196-
1.516) 
<0.0
01 
>=35 
1.776 (1.403-
2.248) 
<0.0
01 
1.976 (1.683-
2.320) 
<0.0
01 
1.799 (1.560-
2.075) 
<0.0
01 
1.705 (1.487-
1.956) 
<0.0
01 
Year of 
Transplantation  
(2007) 
0.975 (0.954-
0.998) 
0.03
0 
0.979 (0.964-
0.995) 
0.00
9 
0.984 (0.970-
0.997) 
0.98
4 
0.985 (0.972-
0.999) 
0.03
3 
 
*No statistical significance and not in the equation.  
The following factors were not statistically significantly associated with outcome at the measured time points: Donor sex, 
cause of death, HBcAb, HCVAb, Recipient sex, HCVAb 
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Figure 1. The use of HTK and UW in the Eurotransplant region 
 
 
 
 2007 2008 2009 2010 2011 2012 2013 2014 2015 2016 
 N % N % N % N % N % N % N % N % N % N % 
HTK 665 64 762 71 806 77 880 75 858 74 929 84 799 79 856 79 843 84 778 82 
UW 370 36 308 29 244 23 291 25 300 26 182 16 208 21 225 21 158 16 166 18 
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Figure 2. Kaplan-Meier survival analysis by preservation fluid (n=10,628) 
a. Graft survival 
 
Preservation fluid category 30 days 1 year  3 year  5 year  
HTK (n=8,176) 
Survival 89% 75% 67% 60% 
N events 897 1,897 2,376 2,628 
N at risk 6,736 5,154 3,141 1,814 
UW (n=2,452) 
Survival 93% 82% 72% 67% 
N events 176 423 625 707 
N at risk 2,206 1,863 1,305 868 
Log rank test UW vs. HTK <0.001 <0.001 <0.001 <0.001 
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b. Patient survival 
 
Preservation fluid category 30 days 1 year  3 year  5 year  
HTK (n=8,176) 
Survival 93% 79% 71% 65% 
N events 547 1,554 2,023 2,273 
N at risk 7,086 5,443 3,360 1,955 
UW (n=2,452) 
Survival 95% 86% 78% 72% 
N events 113 341 509 595 
N at risk 2,269 1,939 1,397 935 
Log rank test UW vs. HTK <0.001 <0.001 <0.001 <0.001 
  28 
 
Figure 3. Kaplan Meier survival analysis of graft survival by preservation fluid and 
transplant region (Germany vs. Non-Germany), (n=10,628) 
 
Transplant region 30 days 1 year 3 years 5 years 
Germany 
(n=6,610) 
HTK 
n=6,147 
Survival 87% 72% 64% 57% 
N events 764 1,577 1,959 2,165 
N at risk 4,927 3,764 2,399 1,420 
UW 
n=463 
Survival 88% 73% 64% 56% 
N events 54 120 154 178 
N at risk 391 311 222 149 
Log rank test UW vs. 
HTK 
0.444 0.707 0.814 0.944 
Non-Germany 
(n=4,018) 
HTK 
n= 2,029 
Survival 93% 83% 76% 70% 
n events 133 320 417 463 
n at risk 1,809 1.390 742 394 
UW 
n= 1,989 
Survival 94% 84% 74% 70% 
n events 122 303 471 529 
n at risk 1,815 1.552 1083 719 
Log rank test UW vs. 
HTK 
0.462 0.365 0.488 0.779 
 HTK between regions <0.001 <0.001 <0.001 <0.001 
 UW between regions <0.001 <0.001 <0.001 <0.001 
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Figure 4. Risk adjusted graft survival  
a. Germany adjusted for all separate risk factors                                              
b. Non-Germany adjusted for all separate risk factors 
c. All transplantations adjusted for all separate risk factors 
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Supplementary files 
  
 
Figure S1. Kaplan Meier survival analysis of graft survival per total ischemic time 
category (ELTR) 
a. Total ischemic time <=6 hours, (n=2,700), p=0.175 
b. Total ischemic time 6-12 hours, (n=6,231), p=<0.001 
c. Total ischemic time >=12 hours, (n=1,697), p=0.448 
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Figure S2. Kaplan Meier survival analysis of graft survival per total ischemic time 
category (ELTR) – Germany  
a. Total ischemic time <=6 hours, (n=1,010), p=0.369 
b. Total ischemic time 6-12 hours, (n=4,219), p=0.287 
c. Total ischemic time >=12 hours, (n=1,381), p=0.207 
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Figure S3. Kaplan Meier survival analysis of graft survival per total ischemic time 
category (ELTR) – Non-Germany 
a.  Total ischemic time <=6 hours, (n=1,690), p=0.539 
b. Total ischemic time 6-12 hours, (n=2,012), p=0.687 
c. Total ischemic time >=12 hours, (n=316), p=0.549 
 
 
